Feline Infectious Disease Testing: FIV, FeLV, and FPV Diagnostic Guide for Veterinary Clinics

Why Feline Infectious Disease Screening Is a Clinical Priority

Feline immunodeficiency virus (FIV), feline leukemia virus (FeLV), and feline panleukopenia virus (FPV) represent three of the most consequential infectious diseases in domestic cat populations worldwide. Together they account for substantial morbidity, mortality, and — in multi-cat environments such as shelters, catteries, and breeding facilities — outbreak events that can destabilize entire colonies.

Despite the availability of accurate, rapid diagnostic tools, these three diseases remain chronically underdiagnosed. The reasons are practical: testing adds appointment time, costs money, and results can be difficult to interpret. This guide cuts through the complexity, providing veterinary clinicians with a clear framework for when to test, which method to choose, how to collect samples correctly, and how to act on results.

The stakes are high. FIV and FeLV are both retroviral infections with lifelong consequences for infected cats. FPV — despite being vaccine-preventable — retains epidemic potential in unvaccinated or immunocompromised populations and carries a mortality rate exceeding 90% in untreated kittens. Getting the diagnosis right the first time is not a luxury; it is a clinical necessity.

Understanding the Three Pathogens

Feline Immunodeficiency Virus (FIV)

FIV is a lentivirus in the Retroviridae family, related to — but distinct from — HIV. It is transmitted primarily through deep bite wounds, making intact male cats who fight outdoors the highest-risk population. Casual contact, shared food bowls, and grooming do not efficiently transmit the virus. Vertical transmission from queen to kitten is possible but relatively uncommon.

Pathogenesis: FIV targets CD4+ T lymphocytes and CD8+ cells, progressively impairing cellular immunity. After initial infection, cats enter a long asymptomatic carrier phase lasting months to years. Eventually, immunosuppression renders cats susceptible to opportunistic infections, chronic stomatitis, lymphoma, and progressive wasting.

Key diagnostic considerations:

• Maternal antibodies from FIV-positive queens can persist in kittens for up to 6 months, causing false-positive antibody results in uninfected kittens
• The FIV vaccine (discontinued in many markets) also induced antibody responses indistinguishable from natural infection by standard antibody tests — vaccination history is essential context
• PCR-based testing detects proviral DNA directly and is the only method that correctly identifies infected kittens born to positive queens (post-maternal antibody clearance confirmation) and distinguishes vaccine-antibody-positive from truly infected cats

Feline Leukemia Virus (FeLV)

FeLV is an oncornavirus (gammaretrovirus) that integrates into the host genome and is transmitted via prolonged close contact — mutual grooming, shared food and water bowls, bite wounds, and in utero transmission from queen to kittens. Unlike FIV, casual transmission is efficient, making FeLV far more contagious in multi-cat households and shelter settings.

Pathogenesis: FeLV suppresses immune function and drives neoplastic transformation, particularly lymphoma and leukemia. Infection outcomes range from progressive infection (persistent viremia, eventual death) to regressive infection (immune control with latent proviral integration) to abortive infection (complete viral clearance). These outcome distinctions have profound implications for prognosis, management, and household contact risk.

Key diagnostic considerations:

• The p27 antigen (viral core protein) is the primary target for rapid antigen and ELISA tests; it detects progressive infection with high sensitivity
• Regressive infections may be p27-antigen negative but PCR-positive for proviral DNA
• A single positive p27 antigen result in a clinically healthy cat should be confirmed with a second test 4–8 weeks later — some cats with early infection seroconvert to negative upon immune control
• IFA (indirect fluorescent antibody) testing of blood smears can confirm progressive infection by detecting p27 antigen within leukocytes and platelets

Feline Panleukopenia Virus (FPV)

FPV (feline parvovirus) is one of the most environmentally stable pathogens in veterinary medicine. It is a single-stranded DNA virus (Parvoviridae) closely related to canine parvovirus type 2 (CPV-2), which can infect cats under some conditions. FPV is transmitted via direct fecal-oral contact or contact with contaminated fomites; the virus survives in the environment for up to one year at room temperature and resists many common disinfectants.

Pathogenesis: FPV targets rapidly dividing cells — intestinal crypt epithelium, bone marrow progenitor cells, lymphoid tissue, and, critically, the developing cerebellum in utero and neonatal kittens. The resulting panleukopenia (profound drop in all white blood cell lines) leaves cats acutely vulnerable to sepsis. Mortality in untreated kittens exceeds 90%; mortality in unvaccinated adults ranges from 25–90%.

Key diagnostic considerations:

• Fecal antigen tests designed for CPV-2 (canine parvovirus) show high cross-reactivity with FPV and are widely used clinically
• Modified live FPV vaccine administered within 5–12 days prior to testing can cause a transient false-positive fecal antigen result — always check vaccination records
• PCR offers the highest sensitivity and can quantify viral load; useful when antigen test is negative but clinical index of suspicion is high
• In peracute cases, cats may die before fecal antigen shedding reaches detectable levels — serology (IgM) or PCR on intestinal tissue post-mortem may be more informative

Diagnostic Method Comparison: Rapid Antigen vs PCR vs ELISA

Selecting the right test method requires matching the clinical question to the technology's strengths and limitations.

Disease-Specific Testing Protocols

FIV Testing Protocol

Recommended test approach:

For adult cats with no FIV vaccination history, the AAFP (American Association of Feline Practitioners) recommends starting with a rapid antigen/antibody combination test. A negative result in a clinically healthy adult cat with low-risk lifestyle is reliable for ruling out infection. A positive result requires confirmation.

For kittens under 6 months of age or cats with known or unknown FIV vaccination history, PCR is the test of choice. Antibody tests (rapid or ELISA) cannot distinguish maternal antibodies or vaccine-induced antibodies from antibodies generated by true infection.

Confirmation algorithm:

1. Rapid combo test positive → repeat with a second rapid test from a different manufacturer, or send blood for laboratory ELISA
2. Both positive → confirm with PCR (proviral DNA detection) — this definitively identifies infected vs. antibody-positive-only animals
3. Discordant results (one positive, one negative) → PCR is the tiebreaker

Sample requirements:

• Whole blood (EDTA or serum/plasma) for rapid and ELISA antibody/antigen tests
• Whole blood (EDTA) for PCR — buffy coat enrichment increases sensitivity
• Minimum volume: 0.5 mL whole blood for rapid tests; 1–2 mL for reference lab PCR

FeLV Testing Protocol

Recommended test approach:

The AAFP recommends testing all cats at adoption/intake, after any known exposure to a FeLV-positive cat, and annually for high-risk cats (outdoor access, multi-cat households with unknown-status cats). Kittens should be tested before entering a multi-cat household regardless of vaccination status.

A single positive p27 antigen result in a clinically healthy cat without symptoms should not be the sole basis for euthanasia. The current AAFP guideline strongly recommends confirmatory testing 8–12 weeks after the initial positive to allow for the possibility of regressive (self-limiting) infection.

Confirmation algorithm:

1. Rapid p27 antigen test positive → confirm with laboratory ELISA (higher throughput, same antigen target)
2. ELISA positive → confirm with IFA (indirect fluorescent antibody) on blood smear, which detects antigen within circulating leukocytes (confirms progressive infection) or PCR for proviral DNA
3. IFA negative + PCR positive → regressive infection (latent provirus; cat is not currently shedding, lower transmission risk)
4. All three positive → progressive infection (highest transmission risk, guarded long-term prognosis)

Sample requirements:

• Serum or plasma for p27 antigen ELISA
• Whole blood (EDTA) for IFA and PCR
• Bone marrow aspirate for PCR in suspected regressive cases where peripheral blood PCR is negative

FPV Testing Protocol

Recommended test approach:

For cats presenting with acute vomiting, diarrhea, and profound lethargy — particularly unvaccinated cats, kittens, or cats in shelter/cattery environments — FPV should be high on the differential list. The fecal antigen test (CPV/FPV cross-reactive ELISA strip) is the first-line point-of-care test.

False-positive risk: Cats vaccinated with modified live parvovirus vaccine within the preceding 5–12 days may shed vaccine virus detectable by fecal antigen test. Always confirm vaccination date before interpreting a positive fecal test.

When fecal antigen is negative but suspicion remains high:

1. Repeat antigen test 24–48 hours later — fecal shedding can be intermittent
2. Send fecal sample for quantitative PCR — detects lower viral concentrations than antigen test
3. In peracute/fatal cases, PCR on intestinal tissue (duodenum/ileum), lymph node, or spleen at necropsy

Hematology correlation: A complete blood count (CBC) showing severe leukopenia (total WBC < 2,000/µL) with profound lymphopenia and neutropenia is highly supportive of FPV in the appropriate clinical context. This is not pathognomonic but adds diagnostic weight when antigen testing is equivocal.

Sample requirements:

• Fecal swab or fresh feces (0.5–1 g) for antigen test and PCR
• Whole blood (EDTA) for CBC
• Rectal swab as alternative when defecation cannot be obtained

When to Test: Clinical Decision Framework

New Cat Intake (Shelter / Cattery / Adoption)

Every cat entering a multi-cat facility should be tested for FIV and FeLV at intake — before mixing with resident cats. FPV testing is indicated if clinical signs are present or if the source environment had known FPV exposure.

Minimum intake testing panel:

• FIV antibody + FeLV p27 antigen (combined rapid test)
• Fecal exam (including FPV antigen if diarrhea is present or source is unknown)

Additional testing for kittens <6 months:

• PCR for FIV (to avoid maternal antibody false positives)
• Repeat FeLV antigen test at 8–12 weeks if initial test is positive

Pre-Vaccination Screening

Vaccinating a cat that is already FeLV-positive provides no therapeutic benefit and may create false security. AAFP guidelines recommend testing FeLV status before initiating the FeLV vaccine series in cats of unknown status. Similarly, knowing a cat's FIV status before vaccination guides risk-based lifestyle counseling.

Pre-vaccination testing indicated when:

• Cat's FIV/FeLV status is unknown
• Cat has not been previously tested
• Cat has had potential exposure (outdoor access, bite wounds, new housemate of unknown status)

Clinical Signs Suggestive of FIV/FeLV

Test promptly when a cat presents with:

• Recurrent or refractory infections (upper respiratory, urinary, skin)
• Unexplained weight loss or chronic anorexia
• Persistent fever of unknown origin
• Oral ulcers, chronic stomatitis, or periodontal disease refractory to treatment
• Lymphadenopathy (especially generalized)
• Neurological signs (FIV can cause neuropathy; FeLV is associated with CNS lymphoma)
• Anemia (especially non-regenerative anemia in FeLV)
• Leukemia or lymphoma confirmed on cytology/histopathology

Clinical Signs Suggestive of FPV

Test immediately when a cat presents with:

• Acute onset vomiting + profuse diarrhea (often hemorrhagic)
• Rapid dehydration
• Severe lethargy or collapse
• Fever followed by hypothermia in advanced cases
• Profound leukopenia on CBC
• History of exposure to sick cats or shelter environment
• Unvaccinated or incompletely vaccinated status

The combination of clinical signs, CBC findings, and fecal antigen testing in context allows a confident clinical diagnosis in the vast majority of cases.

Point-of-Care PCR with the CarryOn Platform

The CarryOn portable PCR analyzer by Yinrui Bio addresses a longstanding gap in feline infectious disease diagnostics: the need for PCR-level accuracy without reference laboratory turnaround time.

The [Feline FeLV-FIV-FPV Screening Triple Test Chip](/en/products/test-chips/feline-triple-screening/) simultaneously detects all three pathogens from a single sample in under 60 minutes. This matters clinically because:

• FIV PCR on the same sample resolves the maternal antibody problem — kittens born to FIV-positive queens can be definitively cleared or confirmed without waiting months for antibody testing
• FeLV PCR identifies regressive infections that are p27-antigen negative, enabling more nuanced prognosis and household management guidance
• FPV PCR achieves the highest sensitivity available, catching early or low-shedding infections that rapid antigen tests miss

The closed microfluidic chip design eliminates cross-contamination risk — critical when running fecal samples from potentially FPV-infected cats alongside blood samples in the same clinic session. The room-temperature-stable reagents require no cold chain, and the fully automated extraction-to-result workflow demands no specialized laboratory training.

For cats presenting with upper respiratory signs that may suggest FIV/FeLV-associated immunosuppression plus primary respiratory infection, the Feline FHV-FCV-Mycoplasma Respiratory Triple Test Chip can be run concurrently on a second CarryOn chip to characterize the full infectious picture in a single clinic visit.

Result Interpretation and Clinical Decision Points

FIV Results

FeLV Results

FPV Results

Sample Collection Best Practices

Proper sample collection directly determines test accuracy. Common collection errors account for a significant proportion of false-negative results in feline infectious disease testing.

For FIV and FeLV (blood-based testing):

• Collect whole blood into an EDTA (purple-top) tube for PCR and CBC
• Collect serum or plasma (red-top or gold-top, allow to clot and centrifuge) for antigen ELISA
• Minimum volume: 0.5 mL whole blood for rapid tests; 1 mL for reference lab
• Store at 2–8 °C if not testing within 4 hours; do not freeze whole blood for rapid tests
• Severely hemolyzed or lipemic samples reduce rapid test accuracy — collect on a fasted cat when possible

For FPV (fecal testing):

• Rectal swab inserted 2–3 cm with gentle rotation is the most reliable sample when defecation cannot be obtained
• Fresh feces (0.5–1 g) collected within 2 hours is optimal
• Avoid samples contaminated with urine or litter substrate — interference with antigen detection
• Use viral transport medium (VTM) if sending to reference laboratory for PCR; refrigerate at 2–8 °C
• For the CarryOn FPV test chip: follow the swab input protocol in the chip insert — the microfluidic system handles extraction automatically

For a detailed walkthrough of collection techniques across sample types, see our veterinary sample collection and handling guide.

Take the Next Step

Accurate feline infectious disease testing is not merely a diagnostic exercise — it has direct consequences for patient welfare, household transmission risk, and responsible colony management. The combination of rapid antigen tests for initial screening and PCR for confirmation or complex cases provides the diagnostic resolution needed for confident clinical decision-making.

• View the Feline FeLV-FIV-FPV Screening Triple Test Chip
• View the Feline FHV-FCV-Mycoplasma Respiratory Triple Test Chip
• Learn how CarryOn's microfluidic PCR technology works
• Read our rapid test vs laboratory testing comparison
• Request a demo or distributor pricing inquiry